Overview

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

Status:
Active, not recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
Phase:
Phase 4
Details
Lead Sponsor:
Medivation, Inc.
Pfizer
Collaborators:
Astellas Pharma Inc
Medivation is now a wholly owned subsidiary of Pfizer Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Treatments:
Abiraterone Acetate
Prednisolone
Prednisone